Alembic Pharma soars 6% on USFDA nod for new drug

Alembic Pharma jumped 6% during Tuesday’s trade on the BSE after the company said that it has received US Food & Drug Administration (USFDA) tentative approval for its abbreviated new drug application (ANDA) for Dabigatran Etexilate Capsules, 150 mg.

 “The tentative approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) PRADAXA Dabigatran Etexilate Mesylate Capsules, Eq to 150 mg base, Boehringer Ingelheim,” said Alembic Pharma in a BSE filing on Monday.

Alembic Pharma was trading at Rs 541.10, up by Rs 25 or 4.84% as at 1306 hours on Tuesday, on the BSE. The stock had hit an intraday high of Rs 545.

Stock view :-

Alembic Pharmaceuticals Ltd is currently trading at Rs 541, up by Rs 24.9 or 4.82% from its previous closing of Rs 516.1 on the BSE.

The scrip opened at Rs 523 and has touched a high and low of Rs 545 and Rs 523 respectively. So far 185976(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 9728.49 crore.

The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 709.3 on 23-Mar-2017 and a 52 week low of Rs 492.25 on 27-Jun-2017. Last one week high and low of the scrip stood at Rs 524 and Rs 497.25 respectively.

The promoters holding in the company stood at 72.68 % while Institutions and Non-Institutions held 14 % and 13.32 % respectively.

The stock is currently trading below its 200 DMA.

Alembic Pharmaceuticals Ltd :-
BSE 541.00 24.90    (4.82%)
NSE 542.25 25.05    (4.84%)


Popular posts from this blog

शेयरों में निवेश के 4 सुनहरे नियम

The Five Biggest Stock Market Myths

How to make money in falling markets?